These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19375669)

  • 1. High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?
    Paillard F
    Arch Cardiovasc Dis; 2009 Mar; 102(3):165-7. PubMed ID: 19375669
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract]   [Full Text] [Related]  

  • 3. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J; Bérard E; Crisan O; Bongard V
    Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
    Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL
    J Am Coll Cardiol; 2008 Apr; 51(15):1512-24. PubMed ID: 18402913
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
    Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE
    Clin Cardiol; 2018 Oct; 41(10):1281-1288. PubMed ID: 30125052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
    Capriotti T
    Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
    [No Abstract]   [Full Text] [Related]  

  • 16. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypertricglyceridemia: prognostic impact and treatment options].
    Custodis F; Laufs U
    Dtsch Med Wochenschr; 2011 Jul; 136(30):1533-42. PubMed ID: 21789752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keeping our eyes on the prize: low density lipoprotein cholesterol.
    de Lemos JA; Khera A
    Am J Cardiol; 2009 Dec; 104(12):1697-8. PubMed ID: 19962478
    [No Abstract]   [Full Text] [Related]  

  • 19. Fenofibrates get a second look. Research shows popular drugs fail to lower cardiovascular risk for most patients already taking a statin.
    Heart Advis; 2010 Jun; 13(6):4-5. PubMed ID: 23166970
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.